Malignant pleural mesothelioma

被引：2

作者：

Ploenes, T. ^{[1
]}

Osei-Agyemang, T. ^{[1
]}

Nestle, U. ^{[2
]}

Waller, C. F. ^{[3
]}

Passlick, B. ^{[1
]}

机构：

[1] Univ Freiburg, Abt Thoraxchirurg, Freiburg, Germany

[2] Univ Freiburg, Klin Strahlenheilkunde, Freiburg, Germany

[3] Univ Freiburg, Innere Med Abt 1, Freiburg, Germany

来源：

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2012年 / 137卷 / 10期

关键词：

intracavitary intraoperative hyperthermic chemotherapy; asbestos; multimodal treatment; mesothelioma; LONG-TERM SURVIVAL; EXTRAPLEURAL PNEUMONECTOMY; PHASE-II; HYPERTHERMIC CISPLATIN; SURGICAL-MANAGEMENT; DIAGNOSIS; SURGERY; TRIAL; PLEURECTOMY/DECORTICATION; CHEMOTHERAPY;

D O I：

10.1055/s-0031-1298905

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Malignant pleural mesothelioma (MMP) is a highly aggressive tumor arising of the pleural mesothelium. Asbestos exposure is the main factor involved in the pathogenesis of MMP and according to the late ban of this agent in 2005 the peak incidence in Europe is expected in the next twenty years. The highly aggressive behaviour of this tumor results in a poor prognosis with a mean overall survival between 7 and 9 months. Despite the progress made in diagnosis and therapy of this entity the optimal treatment remains a subject of debate. In this article we review the current state of treatment and diagnosis. © Georg Thieme Verlag KG Stuttgart New York.

引用

页码：481 / 486

页数：6

共 49 条

[1] MALIGNANT PLEURAL MESOTHELIOMA - A DISEASE UNAFFECTED BY CURRENT THERAPEUTIC MANEUVERS [J].